By Ahmed Abdelsalam
Pharmaceutical and biotech companies invest billions developing new treatments, yet clinical trials frequently face a costly challenge: patient dropout. While recruitment receives significant attention, retention is equally critical to study success. Early departures can extend timelines, increase costs, reduce statistical power, and delay delivery of potentially life-changing therapies.
Practical Barriers Drive Dropouts
Participants are not simply patients; they are parents, caregivers, employees, and students managing complex lives alongside health conditions. Frequent clinic visits, lengthy travel, time away from work, childcare needs, and out-of-pocket expenses create cumulative burdens that can overwhelm even highly motivated individuals.
Patient-Centric Design Needed
Clinical research has often been designed around operational requirements rather than patients' daily realities. A truly patient-centric approach starts by asking what barriers might prevent successful participation. Solutions vary: transportation support, temporary relocation, expense reimbursement, or bringing study visits into the home through decentralized services.
Technology and Human Support
Technology plays an important role in making trials more accessible and efficient, but it cannot solve every challenge. Patients often need flexibility, empathy, and personalized support when unexpected situations arise. Dedicated patient support teams provide problem-solving and adaptability that automated platforms cannot.
Industry Perspective
At mdgroup, the belief that there is no data without people drives the design of patient-centred support programs. Reducing participation burdens and treating each patient as an individual can improve retention, strengthen study outcomes, and accelerate the delivery of new therapies to those who need them most.
